Clinical Trial Detail

NCT ID NCT03285321
Title Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Greg Durm, MD
Indications

lung non-small cell carcinoma

Therapies

Ipilimumab + Nivolumab

Nivolumab

Age Groups: senior adult

No variant requirements are available.